Delineating antibody recognition in polyclonal sera from patterns of HIV-1 isolate neutralization

Science

Volumn 340, Issue 6133, 2013, Pages 751-756

  Georgiev, Ivelin S ^a   Doria Rose, Nicole A ^a   Zhou, Tongqing ^a   Kwon, Young Do ^a   Staupe, Ryan P ^a   Moquin, Stephanie ^a   Chuang, Gwo Yu ^a   Louder, Mark K ^a   Schmidt, Stephen D ^a   Altae Tran, Han R ^a   Bailer, Robert T ^a   McKee, Krisha ^a   Nason, Martha ^a   O'Dell, Sijy ^a   Ofek, Gilad ^a   Pancera, Marie ^a   Srivatsan, Sanjay ^a   Shapiro, Lawrence ^a,b   Connors, Mark ^a   Migueles, Stephen A ^a   Morris, Lynn ^c,d,e   Nishimura, Yoshiaki ^a   Martin, Malcolm A ^a   Mascola, John R ^a   Kwong, Peter D ^a   more..

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

^c NATIONAL INSTITUTE FOR COMMUNICABLE DISEASES   (South Africa)

^d UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^e UNIVERSITY OF KWAZULU NATAL   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

NEUTRALIZING ANTIBODY;

ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNE SYSTEM; NEUTRALIZATION; PHYSIOLOGICAL RESPONSE; SERUM; VIRAL DISEASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY ISOLATION; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MACACA; MOLECULAR RECOGNITION; NONHUMAN; PRIORITY JOURNAL; SERODIAGNOSIS; VIRUS ISOLATION; VIRUS NEUTRALIZATION; VIRUS STRAIN;

EID: 84877618448     PISSN: 00368075     EISSN: 10959203     Source Type: Journal    
DOI: 10.1126/science.1233989     Document Type: Article

References (62)

1. J. Wrammert et al., Nature 453, 667 (2008).
2. J. F. Scheid et al., Nature 458, 636 (2009).
3. E. Traggiai et al., Nat. Med. 10, 871 (2004).
4. X. Wu et al., Science 329, 856 (2010).
5. J. F. Scheid et al., Science 333, 1633 (2011).
6. L. M. Walker et al., Nature 477, 466 (2011).
7. L. M. Walker et al., Science 326, 285 (2009).
8. M. Throsby et al., PLoS ONE 3, e3942 (2008).
9. J. Sui et al., Nat. Struct. Mol. Biol. 16, 265 (2009).
10. B. Bartosch et al., Proc. Natl. Acad. Sci. U.S.A. 100, 14199 (2003).
11. J.-C. Meunier et al., J. Virol. 82, 966 (2008).
12. M. Perotti et al., J. Virol. 82, 1047 (2008).
13. J. Huang et al., Nature 491, 406 (2012).
14. X. Wu et al., Science 333, 1593 (2011).
15. D. Corti et al., PLoS ONE 5, e8805 (2010).
16. E. Delwart et al., J. Infect. Dis. 205, 875 (2012).
17. B. Korber, S. Gnanakaran, Current Opinion in HIV and AIDS 4, 408 (2009).
18. B. Korber et al., Br. Med. Bull. 58, 19 (2001).
19. P. D. Kwong, I. A. Wilson, Nat. Immunol. 10, 573 (2009).
20. D. R. Burton, P. Poignard, R. L. Stanfield, I. A. Wilson, Science 337, 183 (2012).
21. M. Bonsignori et al., Trends Microbiol. 20, 532 (2012).
22. G. B. Karlsson Hedestam et al., Nat. Rev. Microbiol. 6, 143 (2008).
23. Z. Cai, T. Zhang, X.-F. Wan, PLOS Comput. Biol. 6, e1000949 (2010).
24. D. J. Smith et al., Science 305, 371 (2004).
25. R. Pejchal et al., Science 334, 1097 (2011).
26. J. S. McLellan et al., Nature 480, 336 (2011).
27. T. Zhou et al., Science 329, 811 (2010).
28. N. A. Doria-Rose et al., J. Virol. 84, 1631 (2010).
29. Y. Li et al., Nat. Med. 13, 1032 (2007).
30. Y. Li et al., J. Virol. 83, 1045 (2009).
31. J. M. Binley et al., J. Virol. 82, 11651 (2008).
32. E. S. Gray et al., J. Virol. 83, 8925 (2009).
33. L. M. Walker et al., PLoS Pathog. 6, e1001028 (2010).
34. A. K. Dhillon et al., J. Virol. 81, 6548 (2007).
35. P. D. Kwong, J. R. Mascola, Immunity 37, 412 (2012).
36. The 10 clusters included 9 epitope-specific clusters for the monoclonal antibodies and 1 cluster for CD4. Antibody clustering was not solely a function of neutralization breadth: Antibodies within a given cluster could have substantially different neutralization breadth, whereas antibodies in different clusters could have similar neutralization breadth (table S2).
37. A. Trkola et al., J. Virol. 70, 1100 (1996).
38. T. Zhou et al., Nature 445, 732 (2007).
39. Z. Zhu et al., J. Virol. 85, 11401 (2011).
40. R. Diskin et al., Science 334, 1289 (2011).
41. Materials and methods are available as supplementary materials on Science Online.
42. One of the features of our approach is its ability to distinguish between antibodies targeting overlapping epitopes in a substantially different ways: There is a significant difference in the correlation coefficients for antibodies targeting a similar epitope versus the correlation coefficients for antibodies targeting different epitopes on the same site of vulnerability. Similarly, there is a significant difference for similar epitopes versus different sites of vulnerability; however, there is no significant difference for different epitopes on the same site of vulnerability versus different sites of vulnerability (fig. S1).
43. R. M. Cardoso et al., Immunity 22, 163 (2005).
44. Residue numbering throughout the paper is relative to strain HXB2, unless stated otherwise.
45. K. J. Doores et al., Proc. Natl. Acad. Sci. U.S.A. 107, 17107 (2010).
46. Y. Li et al., J. Virol. 86, 11231 (2012).
47. To resolve the discrepancy between epitope mapping and neutralization-based predictions, we determined the cocrystal structure of VRC06 in complex with the gp120 core and compared it with the structure of the VRC01-like antibody VRC03: The antibody variable-domain root mean square deviation upon alignment of the respective VRC06- and VRC03-bound gp120 cores was 1.45 Å, confirming the similarity in the modes of gp120 recognition by these two antibodies (Fig. 2B and table S3). Although VRC03 and VRC06 exhibit extraordinary similarity in their mode of recognition of gp120 when compared with VRC01, unlike VRC01, antibodies VRC03 and VRC06 contain a long insertion in the heavy-chain framework 3 region that falls in the vicinity of the gp120 bridging sheet. In the crystallized complexes of these antibodies and monomeric gp120 core (which lacks the full V1/V2 region), the insertions do not make substantial contact with gp120. On the functional trimer spike, however, these insertions likely make additional contacts with the antigen, extending the antibody epitopes as compared with VRC01. The result is that VRC03 and VRC06 cluster in the periphery of the VRC01 cluster.
48. The division into monoclonal antibody clusters was based on the clustering results from the larger 34-strain panel (Fig. 2A), whereas serum delineation was performed on an available 21-strain panel (because of serum volume constraints, we used a 21-strain subset of the main panel). Although antibody clustering is sensitive to the size of the viral panel (appendix S1), predictions with smaller panels (such as the 21-strain panel used in the serum analysis) could nonetheless be sufficient (fig. S3); delineation of component-antibody specificities for the CAP256 sera was based on a smaller 13-strain panel (41).
49. A signal for PGT128-like antibodies in donor 45 was also observed. However, only part of the neutralization activity of the donor 45 serum could be attributed to VRC01-like antibodies (fig. S11), which indicated that other antibody specificities may also exist in that serum. It is thus not surprising to observe other neutralization signals in the predictions.
50. P. L. Moore et al., J. Virol. 85, 3128 (2011).
51. L. M. Walker et al., Proc. Natl. Acad. Sci. U.S.A. 108, 20125 (2011).
52. Sera were from clade B-infected donors from the cohort described in (28) with moderate to broad neutralization on the panel of 21 viruses.
53. T. Zhou et al ., Retrovirology 9 (Suppl. 2), P57 (2012).
54. For example, standard serum mapping for glycan-V3 antibodies uses N332 mutants and, thus, may not be as sensitive for some antibodies in the PGT128-like group that are more affected by glycan-301 (table S4).
55. The neutralization-based delineation showed relatively strong signals (>0.2) for 2G12- or b12-like antibodies with many of the sera, and potential VRC01-, PG9-, PGT128-, and 10E8-like specificities were predicted for specific subsets of the sera. In the case of 2G12-like activity, many serum samples were also found to be positive by experimental mapping assays, which indicated that this epitope might be a more frequent target compared with other major epitopes, although not necessarily by antibodies having the specific domain-exchanged nature of 2G12 (Fig. 3D). A clear threshold for the presence or absence of a particular specificity in a given serum was not apparent: A level of 0.35 positively identified 10E8-like antibodies in donor N152, but sporadic signals of up to ∼0.3 were observed in longitudinal samples (Fig. 3B).
56. To confirm the predicted similarity to VRC01, we crystallized and determined the structure of the antigen-binding fragment (Fab) of VRC23 in complex with an HIV-1 core gp120. The epitope footprints on gp120 for VRC23 and VRC01 were similar, with buried gp120 surface areas correlating significantly (Spearman R = 0.76, P < 0.0001) (Fig. 4A and figs. S8 to S10).
57. M. D. Simek et al., J. Virol. 83, 7337 (2009).
58. The current analysis is validated primarily for a single major component-antibody specificity in serum, with predictions on other specificities yet to be ascertained; however, the ability to extract major specificities from polyclonal sera will likely be of considerable utility. Nevertheless, the observation that antibody neutralization fingerprints can capture sufficient information to allow, at least in some cases, the deconvolution of the polyclonal serum-based pattern of HIV-1 neutralization into neutralization from component antibodies is subject to a number of assumptions and limitations (41).
59. J. M. Binley et al., J. Virol. 78, 13232 (2004).
60. M. S. Seaman et al., J. Virol. 84, 1439 (2010).
61. Q. J. Sattentau, A. J. McMichael, F1000 Biol. Rep. 2, 60 (2010).
62. F. Klein et al., J. Exp. Med. 209, 1469 (2012).